کارگاه‌های آموزشی مرکز اطلاعات علمی

مقاله نویسی علوم انسانی

اصول تنظیم قراردادها

آموزش مهارت‌های کاربردی در تدوین و چاپ مقاله
Review article

Cancer therapy with phytochemicals: evidence from clinical studies

Azar Hosseini¹, Ahmad Ghorbani¹, ²*

¹Pharmacological Research Center of Medicinal Plants, School of Medicine, Mashhad University of Medical Sciences, Iran
²Neurogenic Inflammation Research Centre, Department of Physiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Article history:
Received: Aug 5, 2014
Received in revised form: Jan 8, 2015
Accepted: Jan 18, 2015
Vol. 5, No. 2, Mar-Apr 2015, 84-97.

* Corresponding Author:
Tel: 05138002283
Fax: 05138828567
ghorbania@mums.ac.ir

Keywords:
Cancer
Phytochemical
Plant
Tumor

Abstract
Cancer is still one of the major causes of mortality in both developing and developed countries. At present, in spite of intensive interventions, a large number of patients suffer from poor prognosis. Therefore, the effort for finding new anticancer agents with better efficacy and lesser side effects has been continued. According to the traditional recommendations and experimental studies, numerous medicinal plants have been reported to have anticancer effect. Also antiproliferative, pro-apoptotic, anti-metastatic and anti-angiogenic effects of several phytochemicals have been shown in in vitro experiments or animal studies. However, only a small number have been tested in cancerous patients and limited evidence exists for their clinical effectiveness. Also, regarding some phytochemicals, only beneficial effects on cancer-related symptoms or on quality of life have been reported and no positive results exist for their antitumor actions. This review was focused on the phytochemicals whose beneficial effects on various types of cancer have been supported by clinical trials. Based on the literature review, curcumin, green tea, resveratrol and Viscum album were the satisfactory instances of clinical evidence for supporting their anticancer effects. The main findings of these phytochemicals were also summarized and discussed.

Please cite this paper as: Hosseini A, Ghorbani A. Cancer therapy with phytochemicals: evidence from clinical studies. Avicenna J Phytomed, 2015; 5 (2): 84-97.

Introduction
Cancer is a growing health problem in both developing and developed countries. According to the recent report of World Health Organization (February, 2014), 8.2 million patients died from cancer in 2012. It has been also estimated that the number of annual cancer cases would have increase from 14 million in 2012 to 22 million within the next two decades (WHO, 2014). Currently, the main treatments for cancer are chemotherapy, radiotherapy and surgery. Some of the most used chemotherapy drugs include antimetabolites (e.g. methotrexate), DNA-interactive agents (e.g. cisplatin, doxorubicin), antitubulin agents (taxanes), hormones and molecular targeting agents (Nussbaumer et al., 2011). However, clinical uses of these drugs are accompanied with by several unwanted effects such as hair loss, suppression of bone marrow, drug resistance, gastrointestinal lesions, neurologic dysfunction and cardiac toxicity.
Cancer therapy with phytochemicals

(Nussbaumer et al., 2011; Monsuez et al., 2010; Dropcho, 2011). Moreover, even with the current intensive interventions, a large number of patients suffer from poor prognosis. Therefore, the search for new anticancer agents with better efficacy and lesser side effects has been continued. Natural compounds are good sources for the development of new remedies for different diseases. Experimentally, several medicinal plants and herbal ingredients have been reported to have anticancer effects (Sharma et al., 2011; Teiten et al., 2013; Tan et al., 2011). Also, a number of phytochemicals isolated from medicinal plants have been shown to decrease cell proliferation, induce apoptosis, retard metastasis and inhibit angiogenesis (Hajzadeh et al., 2006; Tavakkol-Afshari et al., 2006; Mortazavian et al., 2012; Mortazavian and Ghorbani, 2012; Sadeghnia et al., 2014; Shu et al., 2010; Tan et al., 2011). Currently, some of these plant-derived compounds are widely used for chemotherapy of cancerous patients. For example, taxol analogues, vinca alkaloids (vincristine, vinblastine), and podophyllotoxin analogues have played an important role in treatment of such patients (Saklani and Kutty, 2008). This review presents an update of published data on medicinal plants and herbal ingredients that their anticancer effects have been supported by clinical trials (Table 1).

| Phytochemical       | Patients                                      | Study Design                  | Intervention                                                                 | Effect                                                                                           | Reference          |
|---------------------|-----------------------------------------------|-------------------------------|------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|--------------------|
| *Allium sativum*    | Patients with inoperable colorectal, liver,   | Randomized double-blind      | 4 garlic capsules per day for 12 weeks, 4 capsules contained 500 mg of aged garlic extract | Increase of number and activity of natural-killer cells                                        | Ishikawa et al., 2006 |
|                     | or pancreatic cancer                          | placebo-controlled trial     |                                                                              |                                                                                                  |                     |
|                     | Patients with colorectal adenomas             | Randomized double-blind trial| 3 capsules twice a day for 12 months, 6 capsules containing the equivalent of 2.4 ml of garlic | Suppress of size and number of colon adenomas                                                    | Tanaka et al., 2006  |
| Camptothecin        | Patients with refractory cancers              | Phase I clinical trial       | Camptothecin: 3 weeks on drug with a 1-week rest; Nitrocamptothecin: 5 consecutive days with a 2-day rest period | Both compounds lead to tumor regression in a number of patients with breast, prostate and melanoma cancers | Natelson et al., 1996 |
|                     | Patients with primary or metastatic lung cancer| Prospective phase I/II clinical trial | 6.7-26.6 µg/kg/day aerosolized liposomal nitrocamptothecin for 5 consecutive days/week for 1-6 weeks followed by 2 weeks of rest | Stabilization occurred in 3 patients with primary lung cancer and partial remissions were happened in 2 patients with uterine cancer | Verschraegen et al., 2004 |
|                     | Patients with metastatic colorectal cancer.   | Phase II clinical trial      | Intravenous infusion of 100 mg/m² of CPT-11, a new camptothecin derivative, weekly, or as 150 mg/m² every 2 weeks | Partial response was observed in 17 of 63 patients (6 of 40 patients with liver metastases and 11 of 28 patients with lung metastases) | Shimada et al., 1993  |
| Phytochemical | Patients | Study Design | Intervention | Effect | Reference |
|---------------|----------|--------------|--------------|--------|-----------|
| Curcumin      | Patients with urinary bladder cancer, uterine cervical neoplasm, or intestinal metaplasia | Prospective phase I/II clinical trial | 500 mg/day, orally, for 3 month | Histologic improvement in 1 out of 2 patients with bladder cancer, 1 out of 6 patients with intestinal metaplasia and 1 out of 4 patients with uterine cervical neoplasm | Cheng et al., 2001 |
|               | Patients with advanced pancreatic cancer | Nonrandomized open-label phase II trial | 8 g/day curcumin, orally, for one month | Among 21 patients, 1 had stable disease for >18 months and 1 had tumor regression | Dhillon et al., 2008 |
| Green tea     | Patients with high-grade prostate intraepithelial neoplasia | Double-blind placebo-controlled trial | 600 mg/day green tea catechins, orally, for one year | After 1 year, the incidence of prostate development was 3% and 30% in treated and control men, respectively; quality of life improved | Bettuzzi et al., 2006 |
|               | Patients with histologically confirmed adenocarcinoma of the prostate | Case-control study | Usual tea consumption | The prostate cancer risk declined with increasing frequency, duration and quantity of green tea consumption | Jian et al., 2004 |
|               | Patients with esophageal cancer | Case-control study | Usual tea consumption | green tea consumption was associated with reduced risk of esophageal cancer | Gao et al., 1994 |
|               | Patients with colon, rectum and pancreas cancer | Case-control study | Regular, non-regular and high tea consumption | An inverse association with each cancer was observed with increasing amount of green tea consumption | Ji et al., 1997 |
|               | Patients with androgen independent metastatic prostate carcinoma | Pre- and post-treatment | 6 g/day of green tea orally in 6 divided doses for 2 months | Decrease of PSA was seen only in 2% of patients | Jatoi et al., 2003 |
### Table 1. Continued

| Phytochemical      | Patients                                      | Study Design                  | Intervention                        | Effect                                                                 | Reference                  |
|--------------------|------------------------------------------------|-------------------------------|-------------------------------------|------------------------------------------------------------------------|----------------------------|
| Patients with hormone refractory prostate cancer | Self-control study | 250 mg twice daily for 2 months | Among 15 patients, 9 subjects had progressive disease within 2 months and 6 patients developed progressive disease after additional 1 to 4 months of therapy | Choan et al., 2005         |
| Panax ginseng      | Patients with cancer of uterine, ovary, rectum, stomach, etc | Randomized double-blind placebo controlled pilot trial | 3000 mg/day of the heat-processed ginseng for 12 weeks | Improvement of mental and physical functioning | Kim et al., 2006           |
|                   | Patients with stage III gastric cancer          | Not stated                    | 4.5 g/day of ginseng powder for 6 months; patients were followed up for 4.5 years | Significant reduction of cancer recurrence and restoration of CD3 and CD4 levels to the initial preoperative values | Suh et al., 2002           |
| Resveratrol        | Patients with colorectal cancer                 | Phase I pilot study           | 20-80 mg/day of resveratol containing grape powder for 14 days | Resveratol did not inhibit the Wnt pathway in colon cancer but inhibited the pathway in normal colonic mucosa | Nguyen et al., 2009        |
|                   | Patients with colorectal cancer and hepatic metastases | Phase I randomized double-blind pilot study | 5 g/daily for 14 days | Apoptosis increased by 39% in malignant hepatic tissue | Howells et al., 2011       |
|                   | Patients with colorectal adenocarcinoma         | Pre- and post-treatment       | 0.5 or 1.0 g/day resveratol for 8 days, before surgical resection | Decrease of tumor cell proliferation by 5% (P = 0.05). | Patel et al., 2010         |
| Rhus verniciflua   | Patients with metastatic colorectal or pancreatic cancer | Self-control study            | Standardized *R. verniciflua* extract | Increase of overall survival rate | Lee et al., 2009; Lee et al., 2011 |
|                   | Patients with advanced non-small cell lung cancer | Case series                   | 1350 mg/day of *R. verniciflua* stalks extract, orally, for 84-698 day | The extract positively affected disease progression time | Lee et al., 2009          |
|                   | Patients with advanced non-small cell lung cancer | Self-control study            | Allergen-removed *R. verniciflua* extract | The extract positively affected survival rate | Cheon et al., 2011         |
Table 1. Continued

| Phytochemical   | Patients                                                                 | Study Design                              | Intervention                                      | Effect                                                                 | Reference                        |
|-----------------|---------------------------------------------------------------------------|-------------------------------------------|---------------------------------------------------|------------------------------------------------------------------------|----------------------------------|
| *Viscum album*  | Carcinoma of the colon, rectum, stomach, breast and bronchus              | Prospective nonrandomized and randomized matched-pair | Total extract (known as Iscador)                  | Increase (40%) of survival time; Increase (56%) of self-regulation     | Grossarth-Maticek *et al.*, 2001 |
|                 | Colorectal cancer patients (undergoing open tumor resection)              | Prospective sequential randomized controlled trial | Perioperative infusion of Iscador                 | Prevent suppression of natural killer cell activity                    | Schink *et al.*, 2007            |
|                 | Patients suffering from breast, ovarian and non-small cell lung cancer    | Prospective randomized controlled trial    | Standardized extract; sc, 3 times per week (200 mg) for 1-12 weeks | Decrease of side-effects of Chemotherapy; improvement of quality of life | Piao *et al.*, 2004              |
|                 | Patients with breast cancer                                               | Multicentre randomized double-blind placebo-controlled trial | Standardized aqueous extract; sc, 0.5 ml (10-70 ng/ml) twice weekly for 15 weeks | Improvement of quality of life; increase of helper lymphocytes          | Semiglasov *et al.*, 2004        |

**Literature Review and Method**

The clinical studies included in this review were identified through a literature review conducted on Google Scholar, Medline and Science Direct using the key terms *cancer, clinical, plants, herbs and patients*. Only clinical studies investigating the anticancer effect of phytochemicals on cancerous patients were included in the manuscript. Regarding some phytochemicals (e.g. *Aloe vera* and *Withania somnifera*), only beneficial effects on cancer-related symptoms (e.g. fatigue, pain, vomiting, and anorexia) or on quality of life have been reported and no positive results existed for their antitumor actions (Biswal *et al.*, 2013; Su *et al.*, 2004). Reports of these clinical trials have not been included. Also, for some phytochemicals, the number of trials supporting their antitumor actions on cancerous patients was not more than the number of those reporting no anticancer effects. These phytochemicals (e.g. *Punica granatum*) were excluded because their efficacies need to be investigated further.

**Anticancer Phytochemicals**

*Allium sativum* (garlic) has been reported to have a number of medicinal attributes including antidiabetic, hypolipidemic, antimicrobial, antihypertensive and anticancer effects (Hajzadeh *et al.*, 2006; Tavakkol-Afshari *et al.*, 2006; Ghorbani, 2013). Epidemiologic studies have suggested that the consumption of garlic is associated with a protective effect against gastrointestinal cancers (Fleischauer *et al.*, 2000). Recently, it has been demonstrated that garlic intake suppresses the progression of colorectal adenomas in humans (Tanaka *et al.*, 2006). Also, a randomized double-blind placebo-controlled trial showed that administering of garlic increases the number and activity of natural-killer cells in the patients with advanced cancer of the digestive system (Ishikawa *et al.*, 2006). Because increase of natural-killer cell is associated with a favorable tumor outcome, garlic may prevent death due to cancer (Coca *et al.*, 1997).
Camptothecin
Camptothecin is a natural alkaloid which can be extracted from several plant species including *Canptotheca acerminata* and *Mappia foetida* (Natelson et al., 1996). It is a potent antitumor phytochemical that targets topoisomerase I, an enzyme involved in the relaxation of DNA supercoils (Natelson et al., 1996; Li et al., 2006). Several derivatives of camptothecin have been synthesized and are in clinical trials. In a phase I clinical study, 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin were administered to 52 and 29 patients with refractory cancers, respectively. Both compounds showed antitumor effects in a number of patients with breast cancer (disappearance of liver mass), prostate cancer (fall in the rapidly rising PSA level) and melanoma (regression of skin tumor nodules). Also partial responses were observed in a number of patients with cholangiocarcinoma (reduction in widespread liver metastases), breast carcinoma (disappearance of skin metastases) and ovarian carcinoma (Natelson et al., 1996). Another study demonstrated that the administration of aerosolized liposomal 9-nitrocamptothecin caused positive results (stabilization and partial remissions) in some patients with advanced pulmonary malignancies (Verschraegen et al., 2004). Moreover, it was reported that CPT-11 (a new camptothecin derivative) could induce an antitumor effect against metastatic colorectal cancer (Shimada et al., 1993).

Curcumin
Curcumin is a yellow polyphenol (diferuloylmethane) derived from the rhizome of turmeric (*curcuma longa* Linn). Extensive experimental and clinical works over the past decade have addressed its therapeutic effects against several diseases including diabetes, cardiovascular disease, arthritis, gastrointestinal ulcers, nephropathy and hepatic disorders. The beneficial actions of curcumin are related to its anti-inflammatory, antioxidant and cytoprotective properties (Gupta et al., 2013; Alinejad et al., 2013; Noorafshan and Ashkani-Esfahani, 2013). Moreover, it has been represented that curcumin possess anticancer effects through its multiple actions on mutagenesis, cell cycle regulation, apoptosis, oncogene expression and metastasis (Wilken et al., 2011). Different stages of cancer including initiation, promotion and progression can be affected by curcumin. Cheng et al. (2001) showed that this compound improved histologic parameters in 1 out of 2 patients with resected bladder cancer, 1 out of 6 patients with intestinal metaplasia of the stomach and 1 out of 4 patients with uterine cervical intraepithelial neoplasia. In a nonrandomized open-label study, 25 patients with pancreatic cancer were enrolled in an oral curcumin administration. Among them, two patients showed clinical responses: one had stable disease for >18 months and the other had tumor regression (Dhillon et al., 2008). In a study by Sharma et al. (2001), ingestion of curcumin was accompanied by a significant decrease in lymphocytic glutathione S-transferase (GST) activity. The GSTs are a family of phase II detoxification enzymes and have been shown to be involved in the development of resistance to chemotherapy drugs (Townsend and Tew, 2003). The antitumor action of curcumin is mediated via its antiproliferative effect in multiple cancers, inhibitory action on transcription factors and downstream gene products, modulatory effect on growth factor receptors and cell adhesion molecules involved in angiogenesis, tumor growth and metastasis (Wilken et al., 2011).

Green tea
Green tea is a popular beverage which is consumed worldwide especially in Asia, Europe and North America. Several biological properties have been reported for this beverage which include anti-inflammatory, anti-arthritic, antimicrobial,
antioxidative, neuroprotective, antidiabetic, antiangiogenesis and anticancer effects. Green tea contains proteins, amino acids, carbohydrates, minerals, lipids, vitamins and volatile compounds (Chacko et al., 2010; Ghorbani, 2013b). Recent studies have identified that catechins, a type of polyphenols, are active constituents responsible for the most of the biological properties of green tea (Bettuzzi et al. 2006; Chacko et al., 2010). In a double-blind placebo-controlled study, Bettuzzi et al. (2006) showed that green tea catechins were safe and effective for treating premalignant prostate cancer. On the other hand, results of studies of Jatoi et al. (2003) and Choan et al. (2005) showed that green tea has minimal clinical activity against prostate cancer. Besides, case-control studies support the protective effect of green tea against the prostate, esophageal, colon, rectum and pancreatic cancers (Gao et al., 1994; Ji et al., 1997; Jian et al., 2004). Also, preliminary results reported by Shanafelt et al. (2006) suggested that green tea may be useful in the patients with low grade B-cell malignancies.

Panax ginseng

Roots of ginseng have been medicinally used for thousands of years in Asia. Panax quinquefolius (American ginseng), Panax japonicus (Japanese ginseng) and Panax ginseng (Korean or Chinese ginseng) are of the most commonly used ginsengs worldwide (Ghorbani, 2013b). According to the clinical trials, P. ginseng decreases the incidence of cancer and shows beneficial effects in cancerous patients. Case-control studies have revealed that fresh sliced ginseng, the juice, or tea decreases the risk of most types of cancers including pharynx, larynx, esophagus, stomach, colorectal, pancreas, liver, lung and ovary (Yun and Choi, 1990; Yun and Choi, 1995). In a cohort of 1455 breast cancer patients, it was found that consumption of ginseng before cancer diagnosis was associated with increased overall survival rate (Cui et al., 2006). Regarding the quality of life, although Bao et al. (2012) did not find any positive results, Cui et al., (2006) reported that use of ginseng increased this parameter. Further, a randomized placebo-controlled trial showed that P. ginseng improved some aspects of mental and physical functioning in patients with gynaecologic or hepatobiliary cancer (Kim et al., 2006).

Resveratrol

Resveratrol (trans-3, 4′, 5-trihydroxystilbene) is a phytoalexin found in the skin of grapes, peanuts, a variety of berries and some other fruits. It is known to induce potent antioxidant and anti-inflammatory effects and inhibit the proliferation of a variety of cancer cells (Athar et al., 2007; Smoliga et al., 2011). The antiproliferative effect of resveratrol is mediated through the inhibition of several transcription factors, up-regulation of p53, caspases and Bax, and down-regulation of survivin, cyclins and Bcl-2 (Aggarwal et al., 2004). Increase of Bax/Bcl-2 ratio and up-regulation of caspases lead to apoptosis (Ghorbani et al., 2014). The beneficial effects of resveratrol against cancer have been shown in all the stages of carcinogenesis; initiation, promotion and progression (Smoliga et al., 2011). Nguyen et al. (2009) showed that although resveratrol-containing grape powder cannot suppress the Wnt pathway in colon cancer, it could inhibit Wnt target gene expression in normal colonic mucosa of the patients with colorectal cancer. This suggests that resveratrol has a beneficial effect in the initiation and metastasis of colon cancer because Wnts and their downstream effectors regulate the processes involved in tumor initiation, tumor growth, cell death and metastasis (Anastas and Moon, 2013). Consistent with this suggestion, it has been shown that the administration of resveratrol to patients with colorectal adenocarcinoma reduces tumor cell proliferation (Patel et
Cancer therapy with phytochemicals

al., 2010). Also, in the patients with colorectal cancer and hepatic metastases, resveratrol increases caspase-3 in malignant hepatic tissue compared with the tissue from the placebo-treated patients (Howells et al., 2011). The results suggest that consumption of resveratrol induces antitumor effects in human gastrointestinal tract.

**Rhus verniciflua**

*Rhus verniciflua* (the current name is *Toxicodendron vernicifluum*) is native to East Asia and cultivated in some regions of Japan, Korea and China. This plant is known as "lacquer tree" and has been used for many years in traditional Korean medicine for its antioxidant, antimicrobial, anti-inflammatory and anticancer properties (Jianhua et al., 2010; Kim et al., 2013; Lee et al., 2010b). Experimental studies have shown that flavonoids from *Rhus verniciflua* have anti-proliferative and apoptotic activities on various tumor cell lines including human lymphoma, breast cancer, osteosarcoma and transformed hepatoma cells (Son et al., 2005; Jang et al., 2005; Samoszuk et al., 2005 and Lee et al., 2004). A Korean single-center study reported that standardized *R. verniciflua* extract positively affects overall survival rate in the patients with advanced or metastatic pancreatic cancer and in cases with metastatic colorectal cancer (Lee et al., 2009a; Lee et al., 2011). The positive effect on survival rate and disease progression time have been also reported for patients with advanced non-small cell lung cancer, which arise the possibility that *R. verniciflua* has synergetic effects with concurrent therapy agents and may be appropriate in the patients that chemotherapy is not possible (Lee et al., 2009b; Cheon et al., 2011). Recently, Lee et al. (2010b) reported the successful treatment of two patients with metastatic renal cell carcinoma by allergen-removed *R. verniciflua* extract. The beneficial actions of *R. verniciflua* should be considered alongside its allergenic effect which may induce severe contact dermatitis in sensitive individuals (Lee et al., 2009b).

**Viscum album**

*Viscum album* is a species of mistletoe (Santalaceae) and is commonly known as European mistletoe. Phytochemical preparations of mistletoe are among the most frequently prescribed complementary and alternative therapies for cancer in Europe (Kienle et al., 2003). Until 2003, 23 clinical trials were done to investigate efficacy of mistletoe in cancer. Among them, 19 trials reported positive results on survival, quality of life, or tumor remission in cancerous patients (Kienle et al., 2003). Recent works have also shown that a standardized aqueous extract of *V. album* can decrease side-effects of chemotherapy and improve quality of life in cancerous patients (Piao et al., 2004; Semiglasov et al., 2004). Researches have continued on *V. album*-prepared phytochemicals such as Iscador and aviscumine and recent findings are shown in Table 1. Iscador is a lacto-fermented extract of fresh sap of *V. album*. It has been shown that Iscador increases survival time and self-regulation and decreases suppression of natural killer cell activity in patients with carcinoma of the colon, rectum, stomach, breast and bronchus (Grossarth-Maticek et al., 2001; Schink et al., 2007). Besides, Kleeberg et al. (2004) reported that Iscador had no clinical benefit in high-risk melanoma patients. Regarding aviscumine, preclinical studies have demonstrated immunomodulatory effects which may induce positive effect on tumor stabilization (Schöffski et al., 2004; Zwierzina et al., 2011). Yet, further clinical trials are needed to establish the therapeutic value of aviscumine in the management of diabetic cancer.

**Other anticancer phytochemicals**

Some other phytochemicals, in addition to the above-mentioned ones have been
found to have beneficial effects on cancerous patients: *Aloe arborescens* (Lissoni et al., 2009), combretastatins (Stevenson et al., 2003), *Ganoderma lucidum* (Gao et al., 2003), *Nigella sativa* (Hagag et al., 2013), *Panax quinquefolius* (Barton et al., 2010), *Scutellaria barbata* (Perez et al., 2010) and tetrahydrocannabinol (Guzman et al., 2006). However, for each one, only one or two clinical studies from independent authors could be found for support the anticancer effects. Therefore, more clinical works are necessary to confirm their therapeutic values for the cancer management.

**Conclusion**

Since cancer is commonly fatal and increasing in the world, there is an urgent need for finding new remedies. Medicinal plants have been always an important source for the discovery of new therapeutics for human diseases. Therefore, this source may be a good candidate for the development of novel anticancer agents. Among the hundreds of plants that have been studied for cancer, only a small number of them pass *in vitro* experiments and animal studies and are under clinical trials. Based our literature search, *Allium sativum*, camptothecin, curcumin, green tea, *Panax ginseng*, resveratrol, *Rhus verniciflua* and *Viscum album* had satisfactory instances of clinical evidence for supporting their anticancer effects. Therefore, it seems that they can be used as a complementary therapeutics along with current chemotherapy drugs against various types of cancer. Although a number of other phytochemicals could be also added to this list, it is better to remain until more clinical trials support their anticancer effect. An overall weakness of cancer phytotherapy is that in most of related studies there are methodological flaws including lack of control or placebo group, small sample sizes and short duration of trial. Therefore, for many of phytochemicals, it is too early to draw conclusion for their anticancer actions. Moreover, much remains to be learned about pharmacokinetics, drug interactions, ideal dosages, long-term safety and adverse effects of phytochemicals proposed for cancer treatment. On the other hand, fortunately molecular mechanisms responsible for anticancer effect of several medicinal plants have been revealed by *in vitro* studies. These mechanisms include antioxidation, carcinogen inactivation, antiproliferation, cell cycle arrest, induction of apoptosis, and inhibition of angiogenesis or a combination of these mechanisms (Chahar et al., 2011).

It is believed that herbal preparations containing multiple phytochemicals may have greater effects than the same phytochemical taken separately. Based on this belief, combinations of the anticancer phytochemicals may have more effect and yield more potent therapeutic agents for cancer. The initial results are encouraging (de-la Taille et al., 1999; Zhuang et al., 2009) and upcoming clinical trials on this topic are particularly warranted.

**Conflict of interest**

The authors declare that there is no conflict of interests regarding the publication of this paper.

**Acknowledgment**

Salary support was provided by Mashhad University of Medical Sciences.

**References**

Aggrawal B, Bhardwaj A, Aggrawal R, Seeram NP, Hishodia S, Takada Y. 2004. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res, 24: 2783-2840.

Alinejad B, Ghorbani A, Sadeghnia HR. 2013. Effects of combinations of curcumin, linalool, rutin, safranal, and thymoquinone on glucose/serum deprivation-induced cell death. Avicenna J Phytomed, 3: 321-328.
Anastas JN, Moon RT. 2013. WNT signalling pathways as therapeutic targets in cancer. Nature Reviews Cancer, 13: 11-26.

Athar M, Back JH, Tang X, Kim KH, Kopelovich L, Bickers DR, Kim AL. 2007. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol, 224: 274-283.

Bao PP, Lu W, Cui Y, Zheng Y, Gu K, Chen Z, Zheng W, Shu XO. 2012. Ginseng and Ganoderma lucidum use after breast cancer diagnosis and quality of life: a report from the shanghai breast cancer survival study. PLoS ONE, 7: e39343.

Barton DL, Soori GS, Bauer BA, Sloan JA, Johnson PA. 2010. Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Support Care Cancer, 18: 179-187.

Bettuzzi S, Brausi M, Rizzi Federica, Castagnet G, Peracchia G, Corti A. 2006. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res, 66: 1234-1240.

Biswal BM, Sulaiman SA, Ismail HC, Zakaria H, Musa KI. 2013. Effect of Withania somnifera (Ashwagandha) on the development of chemotherapy-induced fatigue and quality of life in breast cancer patients. Integr Cancer Ther, 12: 312-22.

Chacko SM, Thambi PT, Kuttan R, Nishigaki I. 2010. Beneficial effects of green tea: A literature review. Chin Med, 5: 13.

Chahar MK, Sharma N, Dobhal MP, Joshi YC. Flavonoids: a versatile source of anticancer drugs. Pharmacogn Rev 2011; 5: 1-12.

Chen HW, Huang HC. 1998. Effect of Curcumin on cell cycle progression and apoptosis in smooth muscle cells. Br J Pharmacol, 124: 1029-1040.

Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY. 2001. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res, 21: 2895-2900.

Cheon SH, Kim KS, Kim S, Jung HS, Choi WC, Eo WK. 2011. Efficacy and safety of Rhus verniciflua stokes extracts in patients with previously treated advanced non-small cell lung cancer. Forschende Komplementarmedizin, 18: 77-83.

Choo E, Segal R, Jonker D, Malone S, Reaume N, Eapen L, Gallant V. 2005. A prospective clinical trial of green tea for hormone refractory prostate cancer: an evaluation of the complementary/alternative therapy approach. Urol Oncol, 23: 108-113.

Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, Martos JA, Moreno M. 1997. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer, 79: 2320-8.

Cui Y, Shu XO, Gao YT, Cai H, Tao MH, Zheng W. 2006. Association of Ginseng use with survival and quality of life among breast cancer patients. Am J Epidemiol, 163: 645-653.

De la Taille A, Hayek OR, Buttyan R, Bagiella E, Burchardt M, Katz AE. 1999. Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: a preliminary investigation on human cell lines and patients. BJU Int, 84: 845-850.

Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnunakkara AB, Abbruzzese JL. 2008. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res, 14: 4491-4499.

Droppo EJ. 2011. The neurologic side effects of chemotherapeutic agents. Continuum (Minneap Minn) 17: 95-112.

Fleischauer AT, Poole Ch, Arab L. 2000. Garlic consumption and cancer prevention: meta-analyses of colorectal and stomach cancers. Am J Clin Nutr, 72:1047-1052.

Gao YT, McLaughlin JK, Blot WJ, Ji BT, Dai Q, Fraumeni JF Jr. 1994. Reduced risk of esophageal cancer associated with green tea consumption. J Natl Cancer Int, 86: 855-858.

Gao Y, Zhou S, Jiang W, Huang M, Dai X. 2003. Effects of ganopoly (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients. Immunol Invest, 32:201-15.
Hosseini et al.

Ghorbani A, Asadpour E, Sadeghnia HR. 2014. Mechanism of protective effect of garlic against glucose/serum deprivation-induced neurotoxicity. Nutr Neurosci, in press.

Ghorbani A. 2013. Best herbs for managing diabetes: A review of clinical studies. Braz J Pharm Sci, 49: 413-422.

Ghorbani A. Phytotherapy for diabetic dyslipidemia: evidence from clinical trials. Clin Lipidol, 2013; 8: 311-319.

Grossarth-Maticek R, Kiene H, Baumgartner SM, Ziegler R. 2001. Use of Iscador, a extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. Altern Ther Health Med, 7: 57-66.

Gupta SC, Patchva S, Aggarwal BB. 2013. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J, 5: 195-218.

Guzma’n M, Duarte MJ, Bla’quez C, J Ravina, MC Rosa, Galve-Roperh I, Sa’nchez C, Velasco G, Gonza’lez-Feria L. 2006. A pilot clinical study of 9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer, 95: 197-203.

Hagag AA, Abd Elaal AM, Elsheik A, Elzamarany AE. 2013. Protective effect of Nigella Sativa oil against methotrexate induced hepatotoxicity in children with acute lymphoblastic leukemia. J Leuk, 1: 123.

Hajzadeh MR, Tavakkol-Alishari J, Ghorbani A, Shakeri MT. 2006. The effects of aqueous extract of garlic (Allium sativum L.) on laryngeal cancer cells (Hep-2) and L929 cells in vitro. J Med Plants, 5: 41-48.

Howells LM, Berry DP, Elliott PJ, Jacobson EW, Hoffmann E, Hegarty B, Brown K, Steward WP, Gescher AJ. 2011. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res, 4: 1419-1425.

Ishikawa H, Saeki T, Otani T, Suzuki T, Shimozuma K, Nishino H, Fukuda S, Morimoto K. 2006. Aged garlic extract prevents a decline of NK cell number and activity in patients with advanced cancer. J Nutr, 136: 816S–820S.

Jang HS, Kook SH, Son YO. 2005. Flavonoids purified from Rhus verniciflua stokes actively inhibit cell growth and induce apoptosis in human osteosarcoma cells. Biochimica Biophysica Acta, 1726: 309-316.

Jatoi A, Ellison N, Burch PA, Sloan JA, Dakhil SR, Novotny P, Tan W, Fitch TR, Rowland KM, Young CY, Flynn PJ. 2003. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer, 97:1442-1446.

Ji BT, Chow WH, Hsing AW, McLaughlin JK, Dai Q, Gao YT, Blot WJ, Fraumeni JF Jr. 1997. Green tea consumption and the risk of pancreatic and colorectal cancers. Int J Cancer, 27: 255-258.

Jian L, Xie LP, Lee AH, Binns CW. 2004. Protective effect of green tea against prostate cancer: a case-control study in southeast China. Int Journal Cancer, 108: 130-135.

Jianhua S, Kwon YS, Yu CY, Kim M, Kim T, Kim JS, Chun WJ. 2010. Rhus verniciflua stokes flavonoid extracts have antioxidant, anti-microbial and α-glucosidase inhibitory effect. Food Chem, 120: 539-543.

Kienle GS Berrino F, Bussing A, Portalupi E, Rosenzweig S, Kiene H. 2003. A systematic review on controlled clinical trials of green tea against different cancer stages. Eur J Med Res, 8: 109-119.

Kim JH, Park CY. 2006. Effects of Sun Ginseng on subjective quality of life in cancer patients: a double-blind, placebo-controlled pilot trial. J Clin Pharm Ther, 31, 331-334.

Kim KH, Moon E, Choi SU, Kim SY, Lee KR. 2013. Polyphenols from the bark of Rhus verniciflua and their biological evaluation on antitumor and anti-inflammatory activities. Phytochemistry, 92: 113-121.

Kleeberg UR, Suciu S, Bröcker EB, Rüter DJ, Chartier C, Liénard D, Marsden J, Schadendorf D, Eggermont AM; EORTC Melanoma Group in cooperation with the German Cancer Society (DKG). 2004. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or...
Cancer therapy with phytochemicals

Regional lymph node metastasis. Eur J Cancer, 40: 390-402.
Lee JC, Lee KY, Kim J. 2004. Extract from Rhus verniciflua stokes is capable of inhibiting the growth of human lymphoma cells. Food Chem Toxicol, 42: 1383–1388.
Lee S, Kim K, Jung H, Lee S, Cheon S, Kim S, Eo W, Choi W. 2011. Efficacy and safety of standardized allergen-removed Rhus verniciflua Stokes extract in patients with advanced or metastatic pancreatic cancer: a Korean single-center experience. Oncol, 81: 312-318.
Lee SH, Choi WC, Kim KS, Park JW, Lee SH, Yoon SW. 2010b. Shrinkage of gastric cancer in an elderly patient who received Rhus verniciflua stokes extract. J Altern Complement Med, 16: 497-500.
Lee SH, Choi WC, Yoon SW. 2009a. Impact of standardized Rhus verniciflua stokes extract as complementary therapy on metastatic colorectal cancer: a Korean single-center experience. Integr Cancer Ther, 8: 148–152.
Lee SH, Kim KS, Choi WC, Yoon SW. 2009b. The concurrent use of Rhus verniciflua stokes as complementary therapy with second or more line regimen on advanced non-small-cell lung cancer: case series. The Journal of Korean Oriental Medicine 30:112-117.
Lee SK, Jung HS, Eo WK, Lee SY, Kim SH, Shim BS. 2010a. Rhus verniciflua stokes extract as a potential option for treatment of metastatic renal cell carcinoma: report of two cases. Ann Oncol, 21:1383-1385.
Li QY, Zu YG, Shi RZ, Yao LP. 2006. Review camptothecin: current perspectives. Curr Med Chem, 13: 2021-2039.
Lissoni P, Rovelli F, Brivio F, Zago R, Colciago M, Messina G, Mora A, Porro G. 2009. A randomized Study of chemotherapy versus biochemotherapy with chemotherapy plus Aloe arborescens in patients with metastatic cancer. In Vivo, 23: 171-176
Monsuez J, Charniot JC, Vignat N, Artigou JY. 2010. Cardiac side-effects of cancer chemotherapy. Intercardiol, 144: 3–15.
Mortazavian SM, Ghorbani A, Hesari T, Ghorbani A. 2012. Antiproliferative effect of viola tricolor on neuroblastoma cells in vitro. Aust J Herb Med, 24: 93-96.
Natelson EA, Giovannella BC, Verschraegen CF, Fehir KM, De Ipolyi PD, Harris N, Stehlin JS. 1996. Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents. Ann NY Acad Sci, 803: 224-230.
Nguyen AV, Martinez M, Stamos MJ, Moyer MP, Planutis K, Hope C, Holcombe RF. 2009. Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer. Cancer Manag Res, 1: 25-37.
Noorafshan A, Ashkani-Esfahani S. 2013. A review of therapeutic effects of curcumin. Curr Pharm Des, 19: 2032-2046.
Nussbaumer S, Bonnaire P, Veuthey JL, Sändrine F. 2011. Analysis of anticancer drugs: A review. Talanta, 85: 2265-2289.
Patel KR, Brown A, Jones DJL, Britton RG, Hemingway D, Miller AS, West KP, Booth TD, Perloff M, Crowell JA, Brenner DE, Steward WP, Gescher AJ, Brown K. 2010. Clinical pharmacology of Resveratrol and its metabolites in colorectal cancer patients. Cancer Res, 70: 7392-7399.
Perez AT, Arun B, Tripathy D, Tagliaferri MA, Shaw HS, Kimmick GG, Cohen I, Shtivelman E, Caygill KA, Grady D, Schactman M, Shapiro CL. 2010. A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer. Breast Cancer Res Treat, 120: 111-118.
Piao BK, Wang X, Xie GR, Mansmann U, Mattes H, Beuth J, Lin HS. 2004. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res, 24: 303-310.
Sadeghnia HR, Ghorbani Hesari T, Mortazavian SM, Mousavi SH, Tayarani-Najar Z, Ghorbani A. 2014. Viola tricolor induces apoptosis in cancer cells and exhibits antiangiogenic activity on...
chicken chorioallantoic membrane. BioMed Res Int, 2014; 625792.
Saklani A, Kutty SK. 2008. Plant-derived compounds in clinical trials. Drug Discov Today, 13: 161-171.
Samoszuk M, Tan J, Chorn G. 2005. The chalcone butein from Rhus verniciflua stokes inhibits clonogenic growth of human breast cancer cells co-cultured with fibroblasts. BMC Complement Alter Med, 5: 5.
Schink M, Tröger W, Dabidian A, Goyert A, Scheuerecker H, Meyer J, Fischer IU, Glaser F. 2007. Mistletoe extract reduces the surgical suppression of natural killer cell activity in cancer patients. A randomized phase III trial. Forsch Komplementärmed, 17: 9-17.
Scho¨ffski P, Riggert S, Fumoleau P, Campone M, Bolte O, Marreaud S, Lacombe D, Baron B, Herold M, Zwirzina H, Wilhelm W, Lentzen H, Twelves C. 2004. Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European organization for research and treatment of cancer new drug development group. Ann Oncol, 15: 1816-1824.
Semiglasov VF, Stepula VV, Dudov A, Lehmacher W, Mengs U. 2004. The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res, 24: 1293-1302.
Shanafelt TD, Lee YK, Call TG, Nowakowski GS, Dingli D, Zent CS, Kay NE. 2006. Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies. Leuk Res, 30: 707-712.
Sharma H, Parihar L, Parihar P. 2011. Review on cancer and anticancerous properties of some medicinal plants. J Med Plants Res, 5: 1818-1835.
Sharma RA, Ireson CR, Verschoyle RD, Hill KA, Williams ML, Leuratti, Manson MM, Marnett LJ, Steward WP, Gescher A. 2001. Effects of dietary curcumin on glutation S-transferase and malondialdehyde-DNA adducts in rat liver and colon mucosa; relation with drug levels. Clin Cancer Res, 7: 1452-1458.
Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N. 1993. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 gastrointestinal cancer study group. J Clin Oncol, 11: 909-913.
Shu L, Cheung KL, Khor TO, Chen C, Kong AN. 2010. Phytochemicals: cancer chemoprevention and suppression of tumor onset and metastasis. Cancer Metastasis Rev, 29: 483-502.
Smoliga JM, Baur JA, Hausenblas H. 2011. Resveratrol and health – a comprehensive review of human clinical trials. Mol Nutr Food Res, 55: 1129-1141.
Son YO, Lee KY, Lee JC. 2005. Selective antiproliferative and apoptotic effects of flavonoids purified from Rhus verniciflua Stokes on normal versus transformed hepatic cell lines. Toxicol Lett, 155: 115-125.
Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, Giontonio B, Zimmer R, Petros WP, Stratford M, Chaplin D, Young SL, Schnall M, O’Dwyer PJ. 2003. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol, 21: 4428-38.
Su CK, Mehta V, Ravikumar L, Shah R, Pinto H, Halpern J, Koong A, Goffinet D, Le QT. 2004. Phase II double-blind randomized study comparing oral aloe vera versus placebo to prevent radiation-related mucositis in patients with head-and-neck neoplasms. Int J Radiat Oncol Biol Phys, 60: 171-7.
Suh SO, Kroh M, Kim NR, Joh YG, Cho MY. 2002. Effects of red ginseng upon postoperative immunity and survival in patients with stage III gastric cancer. Am J Chin Med, 30: 483-494.
Tan W, Lu J, Huang M, Li Y, Chen M, Wu G, Gong J, Zhong Z, Xu Z, Dang Y, Guo J, Chen X, Wang Y. 2011. Anti-cancer natural products isolated from chinese medicinal herbs. Chinese Medicine, 6: 27.
Tanaka Sh, Haruma K, Yoshihara M, Kajiyama F, Kira K, Amagase H, Chayama K. 2006. Aged Garlic Extract Has Potential Suppressive Effect on
Cancer therapy with phytochemicals

Colorectal Adenomas in Humans. J Nutr, 136: 821S-826S.
Tavakkol-Afshari J, Hajzadeh MR, Ghorbani A, Parsaei H. 2006. Ethanolic extract of Allium sativum has antiproliferative effect on Hep2 and L929 cell lines. Pharmacogn Mag, 2: 29-31.
Teiten M, Gaascht F, Dicato M, Diederich M. 2013. Anticancer bioactivity of compounds from medicinal plants used in European medieval traditions. Biochem Pharmacol, 89: 1239-1247.
Townsend DM, Tew KD. 2003. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene, 22: 7369–7375.
Verschraegen CF, Gilbert BE, Loyer E, A Huaringa, G Walsh, RA Newman, V Knight. 2004. Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced pulmonary malignancies. Clin Cancer Res, 10: 2319-2326.
WHO, 2014. Cancer. Fact Sheet No. 2971, World health organization, geneva, switzerland. http://www.who.int.
Wilken R, Veena MS, Wang MB, Srivatsan ES. 2011. Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer, 10: 12.
Yun TK, Choi SY. 1990. A case-control study of ginseng intake and cancer. Int J Epidemiol, 19: 871-876.
Yun TK, Choi SY. 1995. Preventive effect of ginseng intake against various human cancers: A case-control study on 1987 Pairs1. Cancer Epidemiol Biomarkers Prev, 4: 401-408.
Zhuang SR, Chen SL, Tsai JH, Huang CC, Wu TC, Liu WS, Tseng HC, Lee HS, Huang MC, Shane GT, Yang CH, Shen YC, Yan YY, Wang CK. 2009. Effect of citronellol and the Chinese medical herb complex on cellular immunity of cancer patients receiving chemotherapy/radiotherapy. Phytother Res, 23: 785-790.
Zwierzina H, Bergmann L, Fiebig H, Aamdal S, Schoffski P, Witthohn K, Lentzen H. 2011. The preclinical and clinical activity of aviscumine: A potential anticancer drug. Eur J cancer, 47: 1450-1457.
